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Background. Stem cells from adipose tissue (ADSCs) and platelet-rich plasma (PRP) are innovative modalities that arise due to their
regenerative potential. Objective. The aim of this study was to characterize possible histological changes induced by PRP and ADSC
therapies in photoaged skin.Methods. A prospective randomized study involving 20 healthy individuals, showing skin aging. They
underwent two therapeutic protocols (protocol 1: PRP; protocol 2: ADSCs). Biopsies were obtained before and after treatment
(4 months). Results. PRP protocol showed unwanted changes in the reticular dermis, mainly due to the deposition of a horizontal
layer of collagen (fibrosis) and elastic fibers tightly linked. Structural analyses revealed infiltration of mononuclear cells and depot of
fibrotic material in the reticular dermis. The ADSC protocol leads to neoelastogenesis with increase of tropoelastin and fibrillin.
There was an improvement of solar elastosis inducing an increment of macrophage polarization and matrix proteinases. These
last effects are probably related to the increase of elastinolysis and the remodeling of the dermis. Conclusions. The PRP
promoted an inflammatory process with an increase of reticular dermis thickness with a fibrotic aspect. On the other hand,
ADSC therapy is a promising modality with an important antiaging effect on photoaged human skin.
1. Introduction
The aging skin is a complex biological phenomenon that is
composed of intrinsic and extrinsic processes. Facial aging
is a degenerative process that affects the skin and deep struc-
tures resulting from the action of the intrinsic factor (age)
associated with an extrinsic factor related to exposure to
ultraviolet radiation [1–5]. The connective tissue of the skin
is mainly composed of collagen and elastin. Collagen repre-
sents 70% to 80% of the dry weight of the skin, conferring
mechanical strength and structural integrity. Elastic fiber is
a minor component of the dermis, responsible for skin elas-
ticity, with elastin protein representing 2% to 4% of the extra-
cellular matrix [6]. In photoaging skin, there is progressive
destruction of the entire dermal elastic fiber network, with
thick, tangled, tortuous, degraded, and dysfunctional fibers,
leading to the increased density of the elastic material, result-
ing in a cluster of amorphous and dystrophic elastotic mate-
rial throughout the dermis, forming solar elastosis, the main
feature of photoaging [6].
In recent years, there is an increasing interest in the use of
the regenerative properties of adipose tissue [7, 8]. In this
scope, some studies have suggested the application of fat
grafting (lipotransferring) to improve skin quality [9, 10].
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Animal model studies have described an improvement in
skin texture and, in particular, increased elasticity, hyperpig-
mentation control, and aesthetic improvement of scars,
regardless of etiopathogenesis [11–19].
Zuk et al.’s studies in 2001 [7, 20] identified mononucle-
ated cells in the adipose tissue known as fibroblast-like cells
with high capacity for cell differentiation. Mesenchymal
stem cells, found in the stromal vascular fraction (SVF) of
adipose tissue, are multipotent cells with high potential for
self-renewal and ex vivo expansion, with the ability to differ-
entiate into several cell lineages [21–26]. According to the
International Society for Cell Therapy, minimum criteria
are adopted to define a stem cell: characterization of MSC
requires its phenotyping by identifying the cell surface
membrane markers, its ability to adhere to the plastic sur-
face, and the ability to differentiate into 2 to 3 distinct cell
lineages [27].
Platelet-rich plasma (PRP) has also been described as
having a regenerative effect due to growth factors and
cytokines [28–31]. Currently, PRP therapy is described in
many studies, as well as associated with other treatments
[32–34]. PRP has been used to treat alopecia, acne, traumatic
scars, contractile scars, wrinkles, stretch marks, chronic
ulcers, laser therapy, and postsurgical wound to enhance
the healing process. The PRP preparations have been used
since the 1970s, and they have been increasingly popular
since the 1990s [35]. Since then, different protocols and
ways of preparing PRP have emerged: from conventional
blood centrifugation to innovative systems. It can be acti-
vated by adding collagen, calcium, and/or thrombin, by
glass contact or by freeze/thaw cycles, applied as a platelet
or gel suspension [36–38].
At the moment, the biological mechanisms responsi-
ble for the rejuvenating and regenerative effect on human
skin obtained with the fat graft and/or its components
are not yet clearly understood, and there is no consensus
on the histological and ultrastructural changes that occur
in the skin and subcutaneous tissue, after ADSC and PRP
therapies [39–43].
This study is aimed at evaluating the comparative histo-
logical changes of aged facial skin after subdermal therapy
with PRP and ADSCs.
2. Patients, Materials, and Methods
This is a prospective clinical, randomized, and comparative
study conducted between April 2013 and June 2017 with 20
healthy individuals (ASA 1: English, American Society of
Anesthesiology) [44] of both genders, with ages ranging from
45 to 65 years, presenting photoaging skin variables, different
skin color phototypes (Fitzpatrick) [45, 46], and cervicofacial
sagging. The candidates who participated in this study were
spontaneously submitted to the face-lifting surgical proce-
dure at its end. All patients from northeastern Brazil were
split into two skin therapy protocols: protocol 1 (PRP skin
therapy) and protocol 2 (ADSC skin therapy).
The study was conducted at the Carlos Chagas Filho
Institute of Biophysics, Federal University of Rio de
Janeiro-Brazil, at the Excellion Services Biomedical SA® lab-
oratory in Rio de Janeiro-Brazil, at the Center for Anatomy
and Histology at the University of Verona-Italy and at Per-
forma Ltda clinic, in Natal, RN, Brazil. All patients were
recruited at the author’s private clinic (Natal, RN), by elec-
tronic and/or verbal invitation and sent for clinical, cardio-
logical, laboratory evaluation and signing of an informed
consent form that was in accordance with the ethical princi-
ples of the Declaration of Helsinki 2000 and Istanbul 2008,
following the norms of resolution 466/12 and subsequent
ones of the National Health Council/Ministry of Health. It
was submitted to the Ethics and Research Committee board
to be approved (No. 28.063 at 05-25-2012) and registered
in the Brazilian Registry of Clinical Trials (REBEC) on 04-
07-2013 (RBR-2nn9y2).
Subjects with a smoking habit, with hematologic or
hemodynamic disorders, autoimmune diseases, connective
tissue diseases, diabetes type I or II, other metabolic diseases,
and chronic use of corticosteroids, and those that had been
submitted to recent dermatological or surgical face treat-
ments (e.g., facial peeling) were not included. The direct end-
point of the study was to compare the histological benefits
provided by the subdermal PRP and ADSC therapies.
2.1. Protocol 1: PRP Skin Therapy
2.1.1. Blood Collection. Three 10ml ACD tubes were collected
with 3.2% sodium citrate solution (Vacutainer®, Ref: 369714;
BD Biosciences). The three collected tubes containing blood
were sent to the Excellion® laboratory. All the rules of trans-
portation of human biological material were obeyed accord-
ing to the resolution of the Federal Council of Medicine no.
1,823/2007. Tubes containing blood and 0.5ml of 3.2% cit-
rate solution were subjected to single-operator PRP prepara-
tion and stored at -20°C in a freezer.
2.1.2. Preparation of Platelet-Rich Plasma (PRP). For the
development of the PRP, the protocol adopted by Amable
et al. [28] was chosen. The collected hematic material was
subjected to double centrifugation to ensure the best quality
of the PRP, initially at 300 g for 5 minutes at 18°C and there-
after at 700 g for 17 minutes at 18°C. After the first centrifu-
gation, all plasma above the clot layer (containing red and
white cells (leukocytes)) was collected and named PRP1. This
PRP1 was centrifuged at 700 g for 17 minutes at 18°C. After
this second centrifugation step, the platelet pellet was resus-
pended in 300μl of poor platelet plasma (PPP), constituting
a new fraction called PRP2. Platelet activation was performed
by adding 20mM CaCl2 (PRP2-Ca) (PRP2-Thr, Ref: T6884;
Sigma-Aldrich, St. Louis, Missouri, USA), incubating at
37°C for 1 hour. For PRP2 activation, the samples were
exposed to CaCl2 and centrifuged at 3,000 g for 20 minutes
at 18°C. After activation of platelet growth factors, the solu-
tion was frozen at -20°C in a freezer. The day before applica-
tion, the growth factor solution was thawed and kept
refrigerated at 4°C. This PRP2 product represents a high
platelet concentration (1 × 106 platelets/μl) 6.4 times higher
than blood plasma. All steps were performed in a refrigerated
centrifuge (certified Jouan Br4i, Saint-Herblain, Loire-Atlan-
tique, France) [28].
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2.1.3. PRP Injection Procedure. After the preparation of the
PRP (15-20 days), performed in the Excellion® laboratory,
the PRP was placed in a 1ml syringe (Luer Lock, BD®),
coupled to the 30G needle, containing a high concentration
of platelets (1 × 106 platelets/μl). The application was per-
formed in a subdermal plane in the left retroauricular skin
in an area of 1 cm [2], 1 cm behind the auricular conchal.
2.2. Protocol 2: ADSC Skin Therapy
2.2.1. Adipose-Derived Stem Cell (ADSC) Harvesting. Under
local anesthesia with 0.5% xylocaine and 1,500,000U epi-
nephrine, 10 cc of adipose tissue from the infra-abdominal
region was manually harvested by liposuction, using a 10ml
syringe (Luer Lock; BD®) coupled to a liposuction cannula
of 3mm diameter, 15 cm long, containing 3 distal holes
(Tulip®, USA), with manual vacuum. The lipoaspirate was
transferred to a glass vial containing RPMI culture medium
and antibiotics (amphotericin and ciprofloxacin). It was
transported under refrigeration to the laboratory to be proc-
essed accordingly to the specific protocol to isolate and
expand ADSC.
2.2.2. Isolation, Expansion, Characterization, and
Differentiation of Adipose Mesenchymal-Derived Stem Cells
(ADSCs). Following the protocol originally described by
Zuk et al. [7, 20], a 10ml sample of the lipoaspirate was
weighed after washing in sterile phosphate-buffered saline
(PBS), pH 7.4, dissociated with collagenase IA (Sigma-Aldrich,
USA), 200U/mg of tissue, and incubated at 37°C under con-
stant agitation for 1h. The material was then centrifuged,
and the pellet was filtered through a nylon mesh of 70μm.
The cells were resuspended in culture medium supplemented
with 10% fetal bovine serum (FBS), quantified using Trypan
Blue, and plated in the low-glucose Dulbecco’s medium
(DMEM-Low, LGC) supplemented with 20% FBS and antibi-
otics (100U/ml penicillin, 100μg/ml streptomycin). The fol-
lowing day (one passage), nonadherent cells were removed,
and adherent cells were expanded in culture bottles.
Two days before application, the cells were washed with
physiological saline and incubated in the culture medium
supplemented with autologous plasma at 37°C under 5%
CO2 to remove the potentially retained compounds of the
bovine serum. One day before application, 1ml Luer
Lock®-type syringes were prepared containing each 2 million
cells, diluted in 0.4ml of physiological saline, and transported
to the ambulatory facilities for injection.
ADSCs were characterized using combinations of sur-
face markers of the mesenchymal cells, pericytes, and fibro-
blasts: CD105, CD90, CD73, CD14, CD45, CD34, and
HLA-DR. The functional characterization of the cultured
ADSCs was done after induction of differentiation in vitro
to the osteogenic and adipogenic lineages following Zuk
et al. protocol [7, 20].
2.2.3. ADSC Injection Procedure. The expanded ADSCs were
conditioned in 1ml syringes attached to 30G needle, con-
taining 2 × 106 cells in 0.4ml PBS. The ADSCs were injected
into the patient’s subdermal skin, in an area of 1 cm [2] in the
left preauricular region, 1 cm distally forward the tragus.
2.3. Skin Biopsies. Two pretreatment excisional skin biopsies
(control biopsy =untreated skin) of the left retroauricular (3-
5mm posterior to the retroauricular groove) and preauricu-
lar regions (at 3-5mm anterior to the tragus) were performed
under local anesthesia with xylocaine 0.5% and epinephrine
1,500,000U. Biopsies of a PRP- and ADSC-treated skin were
taken after a 3-4 months of interval, during the procedure of
face lifting. All the skin specimens were split into two parts.
One part was submitted to paraffin embedding, and 4μm
microtome slices were stained with hematoxylin-eosin (HE)
and orcein with previous oxone oxidation to detect neo-
formed elastic fibers, as well as to immunohistochemistry.
Another part was sent to the Center for Anatomy and Histol-
ogy at University of Verona-Italy for ultrastructural analysis
by scanning and transmission electron microscopy (SEM
and TEM).
2.4. Immunohistochemistry. Paraffin sections were obtained
and submitted to immunohistochemical techniques. The fol-
lowing antibodies were used: anti-tropoelastin (rabbit poly-
clonal, PR398, Elastin Products Co., Owensville, Missouri,
USA), anti-fibrillin-1 (rabbit polyclonal, PR217, Elastin
Products), anti-elastin (rabbit polyclonal, ab21607, Abcam,
Cambridge, USA), anti-metalloproteinase 12 (MMP12) (rab-
bit monoclonal, Abcam), anti-cathepsin K (CAT-K) (mouse
monoclonal, clone EP1261Y, ab52897, Abcam), anti-CD68
(monoclonal mouse, clone KPi, Dako, Carpinteria, USA),
anti-mannose receptor (rabbit polyclonal, 64693, Abcam),
and heme-oxigenase-1 (rabbit polyclonal, ab13243, Abcam).
All reactions were performed using positive controls (breast
cancer for MMP12 and kidney biopsy sections for CAT-K)
and negative controls (instead of primary antibody, incuba-
tion with the same immunoglobulin isotype).
2.5. Histomorphometry. High-resolution images (2048 ×
1536 pixels) were captured with a system of image analysis
consisting of a digital photographic machine (Evolution
VR Cooled Color 13 bits, Media Cybernetics®, Bethesda,
USA) coupled to a light microscope (Eclipse E800, Nikon®,
Japan). For the capture of images, the software Q-Capture
2.95.0, release 2.0.5 (Silicon Graphics Inc., EUA), was used.
After program settings and calibration of color and contrast
for each type of stain, the Image-Pro Plus 4.4.1 software
(Media Cybernetics, Bethesda, MD 2002, USA) was used
for quantification of either the stained or the immune-
stained slices.
2.6. Statistical Analyses. Data were analyzed using SAS 6.112
(SAS Institute, Inc., Cary, NC) and expressed as medians
(interquartile range). The Wilcoxon Rank Sum Test was
used. An overall α level of 0.05 was used as the limit of statis-
tical significance.
3. Results
3.1. Patients’ Follow-Up. Twenty healthy subjects (4 males
and 16 females) that participated in the present study were
followed up regularly for four months after the subdermal
PRP and ADSC injection until the skin removal has been
done during the face-lifting surgery, and qualitative
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information regarding local skin reactions was analyzed.
Local transitory effects were occasionally observed immedi-
ately after the cell injection, such as injection-site erythema,
edema, bruising, or induration. They did not require any
pharmaceutical intervention and returned to the reasonable
skin condition within less than 48 h. No abnormal skin
reactions were observed, such as persisting inflammation,
necrosis, hyperplasic or abnormal cell growth, tumor devel-
opment, or any other adverse events such as vasculitis or
hypertrophic scars.
3.2. Preskin Therapy. The pretreated skin showed different
photoaging pattern of cutaneous elastosis, between the two
regions/protocols. Due to the lower sun exposure in the left
retroauricular region, the structural examination by scanning
electron microscopy (SEM), the dermis showed few deposits
of elastic and collagen fibers, which were scattered irregularly
and intertwined in a network of collagen fibers, sometimes
scattered in the reticular dermis without forming a common
coalescent pattern of the elastosis. On the other hand, the left
preauricular skin presented a solar elastosis, consequent to
skin photoaging due to chronic sun exposure. In the papillary
dermis (zone 1), a decrease of oxytalan and elaunin elastic
network was observed, and in deep dermis (zone 2), the solar
elastosis resulted in accumulation of the dense pathologic
elastin and collagen fibers. These crumbled elastotic deposits
can be directly related to the full loss of the hierarchically
ordered network of elastin fibers, and their structure is not
compatible with a normal elastic response to skin Stresses,
leading to an overall loss of the skin elasticity in both zones
(Figures 1 and 2). This is, in general, expected among the
inhabitants of the NE coast of Brazil. The skin showed a con-
sistent overall photoaged pathology, albeit it was present at
different degrees of intensity (Figures 1(b) and 1(d)). In the
structural examination by scanning electron microscopy
(SEM), the dermis showed large diameter elastic fibers, irreg-
ularly dispersed and intertwined in a network of collagen
fibers, sometimes condensed in the deeper plane of the der-
mis. The latter appeared rather scarce in some areas, but in
others formed dense bundles (Figure 3). The histology
showed a flattened dermal-epidermal junction (DEJ), with a
reduction or a full loss of the dermal papillae. The major der-
mal structure involved in photoaging was the elastin compo-
nent of the dermal extracellular matrix.
3.3. Post PRP Skin Therapy (Protocol 1). Posttreatment
biopsy of the patients showed the following findings.
Treatment with PRP induced changes mainly in the retic-
ular dermis. After the use of PRP, an increase in reticular der-
mis thickness was observed, which resulted in the horizontal
deposition of layers of elastic fibers and collagen. In this layer,
the presence of active fibroblasts was also observed. The sig-
nificant increase in elastic and collagen fibers and the pres-
ence of fibroblasts suggest a fibrotic reaction in some areas.
After the use of PRP, the relationship between subcutaneous

















Young skin Aged skin
(d)(c)
(b)(a)
Figure 1: Histomorphological study of the skin. Skin biopsies: stained by (a, b) hematoxylin-eosin (HE) and (c, d) orcein: with previous
oxidation with oxone to detect new elastic fibers. In (a), histological sections representative of young skin showing an organized
arrangement of the structural components of the dermis with few inflammatory cells. In (b), intense inflammatory infiltrate and presence
of degenerated material in the dermis, characteristic of collagen basophilic degeneration. In (c), microphotography of the elastic system:
oxytalan fibers and elaunin fibers perpendicular to the DEJ; mature elastic fibers positioned horizontally in the deep dermis in a young
skin. In (d), reduction of oxytalan fibers in zone 1 and accumulation of reactive material for oxidized orcein in the papillary and reticular
dermis (actinic elastosis, zone 2). Original magnification: 4x (objective lens).
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the thickening of the reticular dermis developing a barrier
between these elements (Figure 4).
In structural analysis of posttreatment SEM biopsies
(protocol 1: PRP), perivascular areas with mononuclear cell
infiltration are visible in the reticular dermis and the dermoe-
pidermal junction. The structural examination also con-
firmed the histological findings, revealing a large amount of
elastic fibers and collagen mainly arranged parallel to the skin
surface in compact bundles, as well as revealed the presence
of fibroblasts with a large amount of rough endoplasmic
reticulum and large lysosomes. These findings suggest that
PRP stimulated the fibrosis process in the area where it was
injected (Figure 5).
3.4. Post ADSC Skin Therapy (Protocol 2). All the biopsies
of facial sun-aged skin submitted to subdermal injection
of autologous ADSC showed different degrees of improve-
ment of the overall skin structure, with partial or extensive
reversal of the pathological signs typical of solar elastosis.
In the zone 1 dermis, devoid of oxytalan and elaunin elastic
network in the solar elastosis samples, a fully organized
new system was found after the treatment. The regularly
spaced oxytalan fiber bundles were crossing perpendicularly
the region under the DEJ, linking it to the subjacent elastic
fiber diffuse network laid parallel to the skin surface, indicat-
ing indeed an intense neoelastinogenesis in the regeneration
of the solar elastosis (Figures 6(a)–6(c)). Histopathological
analysis showed that the elastin component of the extracellu-
lar matrix of the skin was apparently the principal target of
the therapy.
After the treatment, significant or full removal of the elas-
totic material was observed, associated with regeneration of
the new sizeable elastic fiber network, with the structural
organization compatible with the normal elasticity of the der-
mis (Figures 7(a)–7(c)).
In the deep dermis, both fibrillin and tropoelastin were
also slightly increased after the treatment when the morphol-
ogy of the immune-labeled elastin molecules shifted from
amorphous and crumbled elastotic deposits to the typical
fibrillary structures (Figure 8).
Analysis of the total immune reactivity of cathepsin K
and MMP12 showed a significant increase (p = 0:011 and p
= 0:005, respectively) after treatment with ADSCs, which
could justify the improvement in the elastosis pattern found
in posttreatment skin (Figure 8).
It is notable that after ADSC therapy of sun-aged skin,
the reactivation of cathepsin K expression in dermal fibro-
blasts or in infiltrating cells is observed. This activity required
a second group of enzymes potentially involved in the elasti-
nolysis observed in our mode which were the metalloprotein-
ases, the major one being potentially the macrophage
metalloelastase MMP12 [47, 48]. Similar to cathepsin K, the
total intensity of the MMP12 immune labeling was signifi-
cantly increased after the ADSC treatment of the sun-aged
skin (Figure 8). The activities of the two enzymes were thus
potentially complementary.
Classical macrophage activation upregulates several
matrix MMPs, but the increase of the MMP12 mRNA levels
is mainly associated with the alternative macrophage activa-
tion in the M2 phenotype [49]. All MSC are known to display
an anti-inflammatory effect in the receptor tissues, due in
large part to the induction of monocyte differentiation into
M2 macrophages [50, 51]. Quantification of three markers
of the M2 macrophage phenotype, CD68, CD206 (mannose
receptor (MR)), and heme-oxygenase-1 (HO-1), is shown
in Figure 8. All three showed a significant increase in positive









Figure 3: Photoaging of the skin. Representative photomicrograph
of scanning electron microscopy (SEM): presence of a net of
collagen fibers grouped in a disordered form (c) permeated by a













Figure 2: Definition of zones 1 and 2 of the dermis (40x magnification). Zone 1 is defined as an area delimited between the dermoepidermal
junction (DEJ) and the presence of elastic material deposited in the deep dermis. Another band (zone 2) has been established which comprises
the limits of the elastic material deposited more deeply in the dermis.
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4. Discussion
Skin degenerative changes are related to age, hormonal
changes, exposure to environmental agents, and stress [1–
5]. In dermatology and plastic surgery, PRP has been widely
applied for skin rejuvenation, scalp alopecia, associated with
fat grafts, after laser peeling, and for prevention of hematoma
in facelift procedures [52–56]. Derived growth factor plate-
lets have been described for regenerative purposes [57] and
other studies suggest paracrine effect, angiogenic action,
and cell proliferation inducer [58, 59]. Despite the wide-
spread use of PRP as a regenerative agent, its efficacy has
yet to be confirmed in different clinical protocols, mainly
for effects, the durability of results, proper dosing, prepara-
tion techniques, and comparison of results [35].
In a previous study, the effect of PRP in association with
fat grafting was evaluated through a clinical trial. More pro-
nounced inflammatory infiltrates and higher vascular reac-
tivity were observed, with increased vascular permeability
and a particular reactivity of nerve structures. The associa-
tion of PRP with the graft did not produce the expected
regenerative effect and had no advantages over the use of
expanded ADSCs or SVF-enriched lipograft in skin rejuvena-
tion [60]. However, PRP continues to be described as having
a possible regenerative effect in other protocols due to their








Figure 4: Histological analysis. Skin treatment with PRP: optical microscopy ((a, b) HE stain; (c, d) Picro-Sirius red stain; (e, f) oxidized
orcein stain). (a, c, e) Pretreatment and (b, d, f) posttreatment using the PRP biopsies. In the pretreatment specimens, adipocytes are
located at the boundary of the dermis with the subcutaneous tissue organized in lobules, which are directed vertically toward the surface
of the skin (∗). These lobules form adipose papillae, which in their apical portion show a relationship with sebaceous or sweat glands.
After the use of PRP, fibrosis is apparent through the thickening of the reticular dermis due to elastic fibers and collagen arranged








Figure 5: Scanning electron microscopy of the skin. Structural analysis of the deep layer of the dermis: (a) SEM shows an intense collagen
network and inflammatory cells in reticular dermis (white arrows); (b) MET shows the presence of numerous fibroblasts in reticular
dermis and collagen fibers in formation. f: fibroblast; c: collagen.
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Considering our results with isolated use of PRP in the
skin, we observed that treatment with PRP promoted
unwanted changes in the reticular dermis, mainly due to
the deposition of a horizontal layer of collagen (fibrosis)
and elastic fibers tightly linked creating a type of barrier
between sweat and sebaceous glands with subcutaneous adi-
pose tissue at the dermoepidermal junction [67]. Structural
analyses after treatment with PRP showed infiltration of the
perivascular area with mononuclear cells, visible in the retic-
ular dermis and dermoepidermal junction. These areas
showed blood capillaries and arterioles surrounding mono-
nuclear infiltrates (Figure 5). In the skin treatment protocol
using PRP, significant regenerative aspects in histological
and ultrastructural analysis were not found [67–70]. Other
aspects must be considered such as the half-life of platelet
growth factors after activation (4-6 h), which may require
several applications; and the standardization of terminologies
and protocols to produce PRP, as well as the complete char-
acterization of the final product, is fundamental for the com-
parability of results [28, 29].
Considering the PRP preparation method adopted in our
trial [28], studies on cytokines have focused on the growth
factors such as TGF, PDGF, VEGF, EGF, bFGF, HGF, IGF-
1, PDGF, TGF, and EGF. Mazzocca et al. reported epidermal
growth factor (EGF) which was higher than that in our pro-
tocol [71]. On the other hand, a similar platelet-derived
growth factor (PDGF-AB) concentration (27.4 to 48.8 pg/10
[6] platelets) and a slightly lower transforming growth factor
(TGF-β1) secretion (161.7 to 185.4 pg/10 [6] platelets) were
reported [46]. Other authors reported similar values for
TGF-β1/10 [6] platelets [72–74]. Castillo et al. related similar
finding regarding PDGF-AB and PDGF-BB [75]. Differences
in PRP preparation emphasize the necessity of standardiza-
tion of methods, in order to make the comparative clinical
analyses suitable.
The endpoint of the study was to compare the histologi-
cal benefits provided by the subdermal PRP and ADSC ther-
apies in photoaging skin. Due to the morphofunctional
impairment of elastic fibers during the skin aging process,
several therapeutic models have been used to maintain or
replace elastin and elastic fiber levels [76, 77]. Treatments
to repair and/or regenerate elastic fibers should consider all
molecules involved in elastin and microfibril formation. Elas-




























Figure 6: Photomicrographs representative of histological sections of biopsies before and after treatment with ADSCs. Changes in the pattern
of zone 1 in copies (a) and (b) (oxidized orcein). (a) Pretreatment biopsy showing rare oxytalan fibers in zone 1. (b) Posttreatment biopsy
shows a high density of perpendicular thin oxytalan fiber web stained: oxidized orcein. (c) Graphical representation of the surface density































Figure 7: Photomicrographs representative of histological sections of biopsies before and after treatment with ADSCs. (a) Pretreatment
biopsies showing intense actinic elastosis in the papillary and reticular dermis. (b) After treatment, a reduction in the elastotic mass in the
dermis was observed. Stained: oxidized orcein. (c) Graph of the surface density of the reactive material for oxidized orcein in zone 2
reveals a significant reduction in elastosis (p = 0:005).
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main target of the recommended treatments. The use of tre-
tinoin or retinoic acid in the skin in topical formulations has,
for many years, increased elastin production by increasing
tropoelastine [6, 77, 78] and fibrillin expression [79]. How-
ever, the biggest challenge is overcoming low-level tropoelas-
tin expression in adult skin, meaning that such treatments
are more likely to have only additional benefits on skin elas-
tin density [80], neglecting the role of microfibrils (fibrillin)
as a support structure for neosynthesized elastin deposition
for forming a new elastic fiber. The microfibrils would adopt
the structural function of a scaffold to allow the deposition of
the newly formed elastin. Some mechanisms regulate the
production and degradation of elastic fiber in adults through
cytokines and signalers (TGF-β1, TGF-α, IGF-1, bFGF, EGF,
TNF-a, and IL) by action on gene expression and tropoelastin
transcription [81–93].
In ADSC skin therapy protocol, all analyses of the elastic
system were directed at the reduction or total reversal of solar
elastosis, addressing two issues: [1] regeneration of loss of
oxytalanic and elaunin fiber networks in the papillary dermis
and [2] replacement of pathological deposits of actinic elastin
with a normal fibrillary structure, elastic fibers in the deep
dermis. This remodeling action of the ECM at the elastic sys-
tem level was demonstrated by the increased fiber density of
the smaller diameter elastic system at the expense of new
fibers in zone 1 (under DEJ). The density increase of this
zone probably occurred due to the emergence of new oxyta-
lanic/elaunin fibers shown in Figure 6. This pattern of neoe-
lastogenesis was confirmed by the significant increase in
fibrillin and tropoelastin (Figure 8) in ADSC posttreatment
biopsies. Fibrillin is the main protein that makes up the
microfibrils of oxytalan fiber, and its induction of expression
precedes that of collagen. For this reason, it is considered a
useful biomarker in skin repair processes. On the other hand,
the degradation of the deposited elastic component (elasto-
sis) was observed in the reticular dermis (zone 2)
(Figure 7). Matrix metalloproteinase type 12 (MMP12) and
cathepsin K (lysosomal elastase) are essential regulators of
elastin degradation and are directly involved in extracellular
matrix remodeling and elastotic material degradation pro-
cesses [79, 94–99]. Once activated, cathepsin would not be
able to degrade large polymerized elastic fibers, depending
on the release of other ECM enzymes. It requires a group of
complementary enzymes involved in elastinolysis (metallo-
proteinases), with MMP12 as its main representative and
dependent on macrophage action [95, 96]. The mechanisms
involved in the cellular degradation of cutaneous elastosis
related to the presence of type M2 macrophages were ana-
lyzed using M2 markers (CD 206: receptor mannose), which
showed a significant increase in skin biopsies after treatment
with ADSCs.
In ADSC-treated skin, inflammatory cells may be impli-
cated in the resolution of the ECM repair and reorganization
process by polarizing the macrophage population to M2 [49].
These findings suggest a direct contribution of ADSCs to skin
regeneration [42]. Macrophages regulate various matrix
metalloproteinases (MMPs), but the increase in MMP12
mRNA levels is mainly associated with the alternative activa-
tion of macrophages with M2 phenotype [94]. All MSCs are
known to have an anti-inflammatory effect on tissues due
to largely inducing macrophage polarization to M2 [100–
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Figure 8: Immunohistochemical analysis after ADSC skin therapy into two aspects: neoelastogenesis represented by anti-fibrillin immune
labelling that showed overall increase of fibrillin, including in the zone 1 (p = 0:001), and anti-tropoelastin immune labelling that showed
increase of the tropoelastin reactive material in the post treatment biopsy (p < 0:05). Extracellular matrix (ECM) remodeling was
represented by anti-cathepsin K immunostaining that revealed an increase in quantity of CAT-K immune-labelled cells in the dermis of a
posttreated skin biopsy (p = 0:011), anti-MMP12 immunostaining representation of percentage of MMP12 in the skin biopsies
significantly increased after ADSC treatment (p = 0:005), anti-CD68 and CD206 (mannose receptor (MR)) macrophage immunostaining
in sun-exposed facial skin before and after ADSC injection that showed a significant increase after ADSC treatment in the dermis of
posttreated skin biopsy (p < 0:05).
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in dermal tissue samples that received treatment with
ADSCs. Quantification of M2 macrophages by CD206 (man-
nose receptor (MR)) revealed the increase of this subpopula-
tion in posttreatment biopsies. The anti-inflammatory effect
mediated by MSC in recipient tissues is largely due to the
increase in M2 macrophages in treated tissues [104], and
we propose that this is at least in part one of the major regen-
erative activities of ADSCs in our study model.
Regarding the aspect of biosafety in tissue and cell
transfer, despite the short time interval of the present study
(4 months), between the application of ADSCs and their
effects on tissue samples submitted to the action of ADSCs,
no dysplastic or oncogenic changes in the skin of the pop-
ulation studied were observed as found in the literature
[105]. The mesenchymal cells of the stromal fraction of adi-
pose tissue used in this assay are autologous and homolo-
gous (ADSCs derived from adipose tissue were used
elsewhere with the same histological and embryonic struc-
ture) [105–109].
The limitations of this study were the difficulty of accu-
rately quantifying skin photoaging, morphofunctional analy-
sis of all elements involved in the regenerative process after
treatment with PRP and ADSCs, and knowledge of all
involved biological events and their mechanisms.
The advantages of using isolated stem cells as antiaging
skin therapy over PRP, fat grafting, and/or ADSC-matching
therapies are as follows: there is no risk of cyst formation
and fibrosis, use of small injection volumes with high
regenerative potential, precise application, possibility of
reapplication after reexpansion of stored stem cells, and/or
cryopreserved cell reuse.
The future of this research line is aimed at creating new
possibilities in regenerative therapy not only in skin diseases
but in other clinical applications in the case of organs and
tissues with reduction and/or alteration in the elastic system
(e.g., aneurysms and joint problems), with a better under-
standing of the mechanisms involved and the control of
these processes.
5. Conclusion
It was concluded that the action of PRP when injected on
aged human skin induces an inflammatory process, contrib-
uting to the increase of collagen fiber deposits and the
increase of reticular dermis thickness with a fibrotic aspect,
not bringing any significant tissue regenerative role. On the
other hand, expanded ADSC therapy in photoaged skin is
related to ECM remodeling, increased production of new
elastic fibers, and degradation of elastotic material depos-
ited in the dermis (elastosis), inducing an important regen-
erative effect that could be considered a promising skin
rejuvenation therapy.
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